Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $204.64

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $204.64.

Several equities research analysts have recently issued reports on ASND shares. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, UBS Group initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Loomis Sayles & Co. L P grew its stake in shares of Ascendis Pharma A/S by 35.3% in the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after acquiring an additional 48,120 shares during the last quarter. Rice Hall James & Associates LLC grew its position in Ascendis Pharma A/S by 2.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock worth $22,562,000 after purchasing an additional 3,274 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its position in Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after purchasing an additional 5,371 shares during the last quarter. Maven Securities LTD bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $7,466,000. Finally, Exome Asset Management LLC raised its position in shares of Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after buying an additional 23,849 shares during the last quarter.

Ascendis Pharma A/S Stock Down 0.2 %

ASND stock opened at $157.94 on Tuesday. The company has a 50 day moving average of $143.63 and a two-hundred day moving average of $136.75. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37. The company has a market cap of $9.59 billion, a price-to-earnings ratio of -22.25 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.